Cargando…
Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
Autores principales: | Robinson, Philip C, Richards, Duncan, Tanner, Helen L, Feldmann, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832144/ https://www.ncbi.nlm.nih.gov/pubmed/33521660 http://dx.doi.org/10.1016/S2665-9913(20)30309-X |
Ejemplares similares
-
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
por: Feldmann, Marc, et al.
Publicado: (2020) -
The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19
por: Robinson, Philip C., et al.
Publicado: (2020) -
Plans for EU disease control centre given boost
Publicado: (2013) -
Plans for EU disease control centre given boost
Publicado: (2013) -
Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant?
por: Chhibba, Tarun, et al.
Publicado: (2022)